10

May 10, 2019

Atrasentan-based therapy for Cardiac repair and myocardial infarction: Atrasentan, a drug used in the treatment of cancer,  pulmonary hypertension and others, increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 10/May/2019,  11.48 pm

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]
May 10, 2019

Amino acid-based Life-extension therapy: Glycine-based combinatorial therapy for Lifespan extension: A therapeutic mix encompassing Glycine, Catalpol, Ursolic acid, Isoliquiritigenin, Maresin, DIM, Ursolic acid  Lutein, Maresin, Cholecalciferol (GCUIMDULMC) activates autophagy, promotes leanness, increases insulin sensitivity, improves motor function, alleviates ageing feature and extends lifespan via upregulation of its target gene ATG5 (Autophagy-related 5), 10/May/2019, 11.14 pm

Introduction: What they say A study from the Global Research Laboratory, Seoul National University, Korea shows that “Overexpression of Atg5 in mice activates autophagy and extends lifespan.” This study was […]
May 10, 2019

Vasoactive Intestinal Peptide (PHM27/VIP)-based therapy protects against Cardiomyopathy: Vasoactive Intestinal Peptide (PHM27/VIP), a peptide hormone consisting of 28 amino acids that promotes contractility, vasodilation, glycogenosis, arterial blood pressure and others, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via upregulation of its target gene, 10/May/2019, 7.01 am

Introduction: What they say A recent study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart […]
May 10, 2019

Revealing the anti-diabetic agent in the known anti-cancer agent Bexarotene: Bexarotene-based therapy for body weight control, energy homeostasis and TIIDM:Bexarotene inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 10/May/2019, 6.44 am

Introduction: What they say  A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]